The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
J BUON
; 12(2): 245-52, 2007.
Article
in En
| MEDLINE
| ID: mdl-17600880
ABSTRACT
PURPOSE:
The aim of this study was to determine the influence of dexamethasone in the decrease of cisplatin and etoposide-induced nausea and vomiting in patients treated for lung cancer during and after 2 chemotherapy cycles. PATIENTS ANDMETHODS:
The analysis included 60 patients with histologically proven lung cancer, who were divided in two groups. Group A consisted of 30 patients who received cisplatin and etoposide with standard antiemetic drugs ondansetron [serotonin receptor antagonist (5-HT(3) antagonist)] and metoclopramide (dopamine receptor antagonist). Group B consisted of 30 patients who received the same chemotherapy regimen with the previous antiemetic therapy plus dexamethasone 8 mg intravenously (i.v.) per day during the 3 days of chemotherapy. During and after the 3-day therapy, patients filled in a questionnaire issuing adverse effects of chemotherapy concerning many symptoms including nausea and vomiting. The results were statistically processed.RESULTS:
There was a significant decrease in the frequency and toxicity of nausea, acute and delayed vomiting in the group of patients who received antiemetic treatment with ondansetron, metoclopramide plus dexamethasone.CONCLUSION:
Dexamethasone administered with 5-HT(3) antagonists and dopamine receptor antagonists significantly decreases the chemotherapy-induced nausea and vomiting.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vomiting
/
Dexamethasone
/
Antineoplastic Combined Chemotherapy Protocols
/
Lung Neoplasms
/
Antiemetics
/
Nausea
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J BUON
Journal subject:
NEOPLASIAS
Year:
2007
Document type:
Article